CLINICAL TRIALS PROFILE FOR APREPITANT
✉ Email this page to a colleague
505(b)(2) Clinical Trials for APREPITANT
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Indication | NCT00090155 ↗ | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2003-09-26 | The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay. |
| New Indication | NCT00090246 ↗ | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-05-13 | The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal surgery requiring overnight hospital stay. |
| New Combination | NCT01012336 ↗ | Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2010-05-01 | The current recommended guideline for patients receiving moderately emetogenic chemotherapy (MEC) is the combination of a 5-HT3 receptor antagonist and corticosteroid. Incidence of chemotherapy induced nausea and vomiting (CINV) is approximately 50% in patients receiving MEC. An incidence rate of 25-38% for delayed emesis and 55-60% for delayed nausea has been observed. Hence, there is clearly a need for more effective prevention of CINV in patients receiving MEC, especially in women with ovarian carcinoma who are particularly susceptible to these symptoms. Therefore the investigators designed a study with the objective to evaluate if new combination (Aprepitant/Ramosetron/Dexamethasone) may improve actual CINV control in ovarian carcinoma patients treated with taxane/carboplatin. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for APREPITANT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00034983 ↗ | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2001-10-29 | A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression |
| NCT00035048 ↗ | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2001-11-21 | A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression. |
| NCT00035282 ↗ | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2001-09-01 | A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for APREPITANT
Condition Name
Clinical Trial Locations for APREPITANT
Trials by Country
Clinical Trial Progress for APREPITANT
Clinical Trial Phase
Clinical Trial Sponsors for APREPITANT
Sponsor Name
